US84833T1034 - Common Stock
NASDAQ:SPRO (10/4/2022, 10:28:53 AM)+0.01 (+0.5%)
|GICS Sector||Health Care|
|Earnings (Last)||08-10 2022-08-10/amc||Earnings (Next)||11-08 2022-11-08|
|Ins Owners||2.62%||Inst Owners||57.33%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant (MDR) bacterial infections, and rare diseases where there is unmet medical and patient need. Its lead product candidate, tebipenem pivoxil hydrobromide (tebipenem HBr) is designed to be the first oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Its pipeline also includes SPR720 and SPR206. SPR720 is designed to be the first oral treatment for non-tuberculous mycobacterial (NTM) infection. SPR206 is a direct acting intravenous (IV) administered polymyxin analogue developed from its potentiator platform to treat MDR Gram-negative bacterial infections within the hospital.
SPERO THERAPEUTICS INC
675 Massachusetts Ave Ste 14
Cambridge MASSACHUSETTS 02139
CEO: Ankit Mahadevia
Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH...
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.
Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK).
It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement.
Here you can normally see the latest stock twits on SPRO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.